Inspira Technologies Receives $580,000 Purchase Order from NYU Langone for FDA-Cleared ART100 System

Inspira Technologies announced on May 18, 2026, that it has received a $580,000 purchase order from NYU Langone Hospital for its FDA-cleared ART100 extracorporeal blood circulation systems. This order follows a successful multi-patient clinical evaluation at the hospital, where the ART100 systems were used in over 30 cases. The evaluation demonstrated the system's operational value and led to the hospital's decision to transition to commercial procurement. This milestone is significant as Inspira is also engaged in strategic discussions regarding its ART100 platform and other medical assets. The ART100 system is intended for cardiopulmonary bypass procedures and is currently under evaluation at other U.S. hospitals. Inspira Technologies, a technology company also involved in advanced connectivity and electronics manufacturing, views this purchase order as a key commercial reference point in its ongoing strategic process.